Hamlet Pharma Braces for Pivotal May 22 Report as Stock Cools, Phase III Looms

Hamlet BioPharma's May 22 interim report will reveal Phase III trial progress for Alpha1H in bladder cancer, cash position, and stock's key support at 6.00 SEK.

The coming week brings a moment of truth for Hamlet BioPharma. After a powerful run that lifted shares more than 54% over the past year, the stock has recently lost some steam, slipping nearly 4.6% in the last five trading days. That pullback leaves the company with a market capitalisation of roughly 1.03 billion Swedish kronor and sets the stage for the interim report due on 22 May 2026. With the third-quarter update promising far more than just financial figures, investors are bracing for clinical and commercial catalysts that could set the direction for the weeks ahead.

Technically, the equity finds itself in a split picture. The medium-term uptrend channel remains intact, signalling that broader optimism has not evaporated. However, a short-term support break has raised caution. The key levels to watch now stand at 6.00 SEK on the downside and 8.80 SEK as resistance, making the 22 May report a potential pivot point for the share price.

At the heart of the narrative sits Alpha1H, a novel neoadjuvant therapy targeting low-risk, non-muscle-invasive bladder cancer. Hamlet is preparing to move this asset into a pivotal Phase III trial, and the US Food and Drug Administration has already supplied written feedback that backs the proposed development pathway. The agency weighed in on primary and key secondary endpoints, including complete response rate, duration of response, and event-free survival. It also endorsed the use of central pathology reviews and blinded independent assessments. Hamlet had aimed to incorporate those recommendations and begin enrolling trial sites in the first or second quarter of 2026, so any progress on the protocol, site selection, or enrolment timeline in the upcoming report could move the stock more sharply than routine quarterly numbers.

The case for Phase III rests on a sturdy Phase II foundation. In the high-dose cohort, 80% of tumours responded to Alpha1H, with an average tumour shrinkage of 59%. No serious drug-related adverse events were reported. At the molecular level, the company documented tumour cell apoptosis, shedding of tumour cells into urine, and sustained effects across repeated treatment cycles, plus the down-regulation of more than 700 cancer-related genes. While these data make for a compelling story, they await definitive confirmation in a larger study.

Bladder cancer itself provides a clear medical rationale. After initial surgical intervention, recurrence rates run as high as 70% to 80%. In Europe alone, total costs exceed €4.9 billion, according to the company.

For a biotech standing on the cusp of a late-stage trial, liquidity is no side issue. The 22 May report will be the first financial update since the February numbers, so the cash position, financing headroom, and costs of Phase III preparation will all come under scrutiny.

Alongside the clinical track, Hamlet is pursuing a commercial path in Germany. Through its subsidiary Alpha1H BC and partner Linnane Pharma, the company signed a non-binding letter of intent with an unnamed uro-oncology specialist based in northern Germany. The aim is to create a potential framework for further development and global commercialisation of Alpha1H in bladder cancer. No binding contract has emerged yet, and PharmaVentures is advising the process as a partnering and licensing consultant. An update on this front would show whether commercial interest is hardening into a concrete deal path.

Alpha1H is not the only iron in the fire. Hamlet is also working with ImmunoForge on a novel delivery technology for NZX, an antimicrobial peptide drug candidate targeting pulmonary tuberculosis. That broadens the pipeline but is unlikely to move the needle in the near term compared with the bladder cancer programme.

Come 22 May, the market will focus on three things: the status of the Phase III protocol, the financing to fund the next clinical stage, and the progress of the German letter of intent. After a strong annual run, a solid story alone is no longer enough — Hamlet now needs to deliver tangible steps forward.